Furosemide Tablets Solicitation
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DLA TROOP SUPPORT
Contract Value
Not provided
Codes & Classification
Solicitation Number
SPE2D2-26-R-0005
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
Documents3
The Defense Logistics Agency (DLA) Troop Support, operating under the Department of Defense, has issued a presolicitation notice for the procurement of Furosemide Tablets. This solicitation, identified by procurement number SPE2D2-26-R-0005, falls under the North American Industry Classification System (NAICS) code 325412, which pertains to Pharmaceutical Preparation Manufacturing. The associated Product Service Code is 6505, indicating a focus on drugs and biologicals.
The primary objective of this procurement is to secure a reliable supply of Furosemide Tablets, a critical pharmaceutical product used in various medical settings, particularly for the management of fluid retention and hypertension. The intended outcome is to ensure that the Department of Defense and its supported entities have consistent access to high-quality Furosemide Tablets to meet operational and healthcare requirements.
The scope of this solicitation encompasses the manufacturing and delivery of Furosemide Tablets in accordance with federal standards and specifications. Contractors are expected to demonstrate the capability to produce pharmaceutical-grade products that comply with all applicable regulatory requirements. Key deliverables will include the timely and compliant supply of Furosemide Tablets, with detailed requirements and specifications likely outlined in the solicitation attachments available through the provided SAM.gov link.
This opportunity is managed by DLA Troop Support, a federal office within the Defense Logistics Agency. Interested parties may direct inquiries to the primary contact, Nancy Fernandez, at [email protected] or 445-737-0713, or to the secondary contact, Jason C. Wray, at [email protected] or 445-737-6304. The notice remains active, with Amendment 2 extending the closing date for responses to June 18th, 2026, at 3:00 PM EST.
Contractors considering this opportunity should note that it is a presolicitation notice, indicating that the formal solicitation will follow. The procurement is classified under pharmaceutical manufacturing, and all interested vendors must be capable of meeting the stringent quality and regulatory standards required for supplying pharmaceuticals to the federal government. No specific set-aside requirements or special considerations are indicated in the current notice.
For further details, including solicitation attachments and updates, contractors are encouraged to review the official notice on SAM.gov using Opportunity ID 6849bae053334e919e805c25ec78c874. This procurement represents a significant opportunity for qualified pharmaceutical manufacturers to support the Department of Defense’s medical supply chain with a vital medication.